MeiraGTx Holdings plc

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. It operates through the following geographical segments: United States, Ireland, Netherlands, and United Kingdom. Its pipeline includes AAV CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company was founded on March 20, 2015 and is headquartered in New York, NY.

Kadmon Hlds

NEW YORK and BEIJING, Feb. 23, 2021 /PRNewswire/ -- Graviton Bioscience Corporation ("Graviton"), a privately held early-stage drug development company founded by Dr. Samuel Waksal, and Beijing Tide Pharmaceutical Co., Ltd. (Beijing Tide) a subsidiary of Sino Biopharmaceutical Limited...

Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide

MGTX has early proof of concept data for ophthalmic rare disease indications using its gene therapies. It has inked two deals with Janssen, one of them quite lucrative.

MeiraGTx: Early Stage Gene Therapy Developer For Eye Diseases

Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET

MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia

LONDON and NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Evercore ISI 3rd Annual HealthCONx Conference at 10:05 a.m. ET on December 3, 2020.

MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

LONDON and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference. The virtual conference will be held from December 1-3, 2020.

MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

The company announced the pricing of a public offering of common stock.

Why MeiraGTx Holdings Stock Is Down Today

LONDON and NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 of its ordinary shares at a public offering price of $12.85 per share. In addition, MeiraGTx has granted the underwriters a 30-day option to purchase up to an additional 750,000 of its ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds to MeiraGTx from the offering are expected to be approximately $64.3 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters' option. All of the ordinary shares in the offering are being sold by MeiraGTx.

MeiraGTx Announces Pricing of Public Offering of Ordinary Shares

LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an underwritten public offering of 5,000,000 of its ordinary shares. In connection with the offering, MeiraGTx intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 of its ordinary shares. All of the ordinary shares are being offered by MeiraGTx.

MeiraGTx Announces Proposed Public Offering of Ordinary Shares

Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal sensitivity at 12 months Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal sensitivity at 12 months

MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment

LONDON and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barclays Gene Editing & Gene Therapy Summit on Monday, November 16, 2020 at 1:30 p.m. ET.

MeiraGTx to Present at the Barclays Gene Editing & Gene Therapy Summit

LONDON and NEW YORK,, Nov. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the third quarter ended September 30, 2020 and provided an update on recent clinical development and business progress.

MeiraGTx Reports Third Quarter 2020 Financial Results

12-Month Dose Escalation Data from Phase 1/2 Clinical Trial to be Presented 12-Month Dose Escalation Data from Phase 1/2 Clinical Trial to be Presented

MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at AAO 2020 Virtual Meeting

LONDON and NEW YORK, Oct. 03, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced nine-month data from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR, an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP). Data presented today at the EURETINA 2020 Virtual Congress demonstrated significant improvement in vision-guided mobility and retinal sensitivity in treated eyes compared to untreated eyes nine months after treatment.

MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP)

LONDON and NEW YORK, Sept.  28, 2020  (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Chardan 4th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 1:30 p.m. ET.

MeiraGTx to Present at the Chardan 4th Annual Genetic Medicines Conference

- Nine-Month Follow-Up Data to be Presented - - Nine-Month Follow-Up Data to be Presented -

MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual Meeting

MeiraGTx Is A Buy With Multiple Near-Term Catalysts As The Stock Is Weighed Down By Negative Sentiment

- Positive initial data from Phase 1/2 clinical trial of AAV-RPGR for the treatment of XLRP recently presented  - AAV-RPGR to advance into Phase 3 Lumeos clinical trial  - Expands manufacturing capabilities with new facilities in Ireland

MeiraGTx Reports Second Quarter 2020 Financial Results

LONDON and NEW YORK, Aug.  05, 2020  (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Robert K. Zeldin, M.D. as chief medical officer (CMO).

MeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D.

MeiraGTx has been struggling lately, but the selling pressure may be coming to an end soon.

MeiraGTx Sees Hammer Chart Pattern: Time to Buy?

• Data being presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting 

MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients  

MeiraGTx Holdings PLC (MGTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

MeiraGTx Holdings PLC (MGTX) Moves to Strong Buy: Rationale Behind the Upgrade

MeiraGTx: An Exciting Gene Therapy Pick In March 2020

LONDON and NEW YORK, March  02, 2020  (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) designations to AAV-RPGR, MeiraGTx’s investigational gene therapy for the treatment of x-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.

MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa

Does MeiraGTx Holdings PLC (MGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes MeiraGTx Holdings PLC (MGTX) a Strong Momentum Stock: Buy Now?

Coherus BioSciences

Moderna

uniQure

XOMA

The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

News for MeiraGTx Holdings plc Stock (MGTX)